3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
68
Prostatic Neoplasms, Castration-Resistant
6
Metastatic Castration-resistant Prostate Cancer
6
Neoplasms
4
Metastatic Castration Resistant Prostate Cancer
4
Urogenital Neoplasms
3
Prostate Cancer Metastatic
3
Neoplasm Metastasis
3
Metastatic Castration-Resistant Prostate Cancer
3
Genital Neoplasms, Male
3
Breast Neoplasms
3
Prostatic Diseases
2
Neoplasms by Site
2
Genital Diseases, Male
2
Carcinoma, Non-Small-Cell Lung
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Ovarian Neoplasms
1
NSCLC Harboring NRG1 Fusion
1
Metastatic Castration-sensitive Prostate Cancer
1
Metastatic Castration-resistant Prostate Neoplasms
1
Metastatic Castration-resistant Prostate Cancer (mCRPC)
1
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
1
Male Urogenital Diseases
1
Hyperaldosteronism
1
Colorectal Neoplasms
1
Advanced Prostate Cancer
1
Advanced Cancer
1
Adenocarcinoma
1
Interventions
darolutamide
2
pembrolizumab
1
olaparib
1
gedatolisib
1
enfortumab vedotin
1
Radiation Dose Hypofractionation
1
Pluvicto
1
Mitomycin
1
Gemcitabine
1
Fluorouracil
1
Cisplatin
1
Abiraterone Acetate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Male Urogenital Diseases
×
Abiraterone Acetate
×
Clear all
NCT06785636
2026-04-24
P300
Pathos AI, Inc.
Phase 1/2
Recruiting
252 enrolled